hrp0086p2-p967 | Thyroid P2 | ESPE2016

Postoperative Complications of Thyroidectomy in Children with Nodular Goiter

Rogova Olga , Okminyan Goar , Samsonova Lubov , Kiseleva Elena , Latyshev Oleg , Kasatkina Elvira , Mirakov Kirill , Okulov Alexey

Background: Objective and hypotheses: Rate the frequency and structure of post-operative complications of thyroidectomy in children with nodular goiter.Method: Twenty-seven children, 20 girls (14.5±3.64 years) and seven boys (14.68±4.09 years), which were performed thyroidectomy about multinodular goiter (n=23) and single-node goiter (n=4) from 2003 to 2015. Were evaluated complaints of patients, physica...

hrp0082fc12.4 | Obesity | ESPE2014

Pediatric Reference Values for Insulin from oGTT and Prevalence of Hyperinsulinemia in Obese Children

Korner Antje , Scheuermann Kathrin , Neef Madlen , Sergeyev Elena , Vogel Mandy , Kratzsch Jurgen , Kiess Wieland

Background: Evaluation of glucose metabolism is currently based on 2 h glucose during an oral glucose tolerance test (oGTT) or fasting glucose and insulin or A1c, as these are the only parameters where cutoff values exist. This does, however, not adequately reflect the degree of hyperinsulinemia due to insulin resistance in obese children.Objective and design: From frequent glucose and insulin levels during an oGTT of 64 healthy lean children (aged 7.7&#...

hrp0082p2-d2-383 | Fat Metabolism & Obesity (1) | ESPE2014

Fetuin A Serum Levels in Children with Nonalcoholic Fatty Liver Disease

Pampanini Valentina , Inzaghi Elena , Nobili Valerio , Germani Daniela , Puglianiello Antonella , Cianfarani Stefano

Background: Fetuin A is a hepatokine known as a natural inhibitor of the insulin receptor tyrosine kinase and is associated with insulin resistance and nonalcoholic fatty liver disease (NAFLD). Studies on adults provided conflicting results regarding the link between fetuin A and the severity of liver damage in NAFLD. Data on children are limited.Objective: To investigate the relationship between fetuin A, metabolic parameters, and NAFLD in obese childre...

hrp0082p2-d3-392 | Fat Metabolism & Obesity (2) | ESPE2014

HbA1c and Metabolic Parameters in a Pediatric Overweight/Obese Population

Pellegrin Maria Chiara , Grillo Andrea , Faleschini Elena , Tornese Gianluca , Ventura Alessandro

Background: HbA1c was recommended as diagnostic tool in adults at risk for diabetes. In obese patients, HbA1c shows an association even with other features of metabolic syndrome. However, its value in pediatric population for this purpose has yet to be established.Material and methods: We determined HbA1c (IFCC method) in 307 overweight/obese children and adolescents (age 11.4±3.2; range 3.0–17.9 and BMI 27.9±4.7; range 20.4–47.6) val...

hrp0082p2-d1-415 | Growth Hormone | ESPE2014

IGF1 is Associated with a More Favourable Pattern of Body Composition in Obese Children

Inzaghi Elena , Pampanini Valentina , Alessio Paola , Fiori Rossana , Ferroli Barbara Baldini , Cianfarani Stefano

Background: Recent studies have suggested a role of IGF1 as a candidate prognostic marker for cardiometabolic complications of obesity.Objective: To investigate the relationship between IGF1 serum levels and both biochemical and metabolic parameters as well as body composition in a cohort of obese children.Methods: obese subjects (130F/157M), aged 11.2±2.7 years, were studied. Anthropometry, biochemical and metabolic parameter...

hrp0082p2-d3-506 | Perinatal and Neonatal Endocrinology | ESPE2014

Metabolic Profile of Neonates With Different Duration of Gestation and Different Size at Birth

Kocova Mirjana , Palcevska-Kocevska Snezana , Krstevska Marija , Sukarova-Angelovska Elena , Zisovska Elizabeta

Background: Controversial findings about the metabolic profile in newborns depending on the length of gestation and size at birth have been reported.Objective and hypotheses: Insulinemia, adiponectin, and leptin levels are different in children born prematurely and SGA neonates compared to term normal newborns.Method: 196 healthy newborns were studied at the age 3-4 days. Birth weight (BW), birth length (BL), BMI, ponderal index (P...

hrp0082p2-d2-524 | Pituitary (1) | ESPE2014

Pituitary Stalk Interruption Syndrome: a Sequential Manner to Gain Pituitary Hormone Deficiencies with Still Unknown Molecular Basis

Jerez Elena , Echeverria Gabriela , Munoz-Calvo Teresa , Pozo-Roman Jesus , Martos-Moreno Gabriel , Argente Jesus

Background: Pituitary stalk interruption syndrome (PSIS) is characterized by the absence of the pituitary stalk, pituitary hypoplasia and an ectopic posterior pituitary.Objective: We aimed to retrospectively analyze the clinical, auxological, biochemical, and radiological findings in Spanish patients with PSIS.Patients and results: Of 27 patients, 25% were female and 75% male. Perinatal features, auxological and endocrine study at ...

hrp0082p3-d1-705 | Diabetes | ESPE2014

Glycemic Control of Patients with Type 1 Diabetes Using Automated Bolus Calculator Glucometerr

Rojo Jaime Cruz , Lorenzo Lucia Garzon , del Pozo Jaime Sanchez , Gomez Ma Elena Gallego

Background: In the past years, new glucometers with integrated automated bolus calculator, are available in the market for patients whith type 1 diabetes (DM1) in multiple daily injections (MDI) therapy. The limited bibliography about the use of these meters in the pediatric population with DM1, suggests that it may have beneficial effects in terms of glycaemic control and improved quality of life.Objective and hypotheses: The use of a glucometer with an...

hrp0082p3-d3-838 | Growth (2) | ESPE2014

Analysis of the Effectiveness of Treatment with GH in a Tertiary Hospital in the Last 30 Years

Rojo Jaime Cruz , Lorenzo Lucia Garzon , Gomez Ma Elena Gallego , Pozo Jaime Sanchez del

Objective: To analyze the efficacy of GH treatment in pediatric patients in a hospital from 1982 to 2013.Material and methods: Retrospective study whose population are patients who have been or are being treated with GH in a Tertiary Hospital. The following data were collected: indication of treatment, years of treatment, genetic target height, height at start and the end of treatment, with their corresponding S.D.. A simple linear regress...

hrp0082p3-d3-863 | Growth (4) | ESPE2014

Costello Syndrome: What About GH Treatment?

Manolachie Adina , Rusu Cristina , Fadur Alina , Bodescu Ioana , Braha Elena , Mogos Voichita , Vulpoi Carmen

Background: Costello syndrome (CS) is a rare autosomal dominant genetic disease, first described in 1971, part of neuro-cardio-facio-cutaneous syndrome (with RAS pathway genes mutations of MAPKinaza-RASopathies), characterized by short stature, delayed mental development, joint hiperlaxity, papillomas, congenital heart defects and increased risk to develop benign or malignant solid tumors.Case: We present the case of a teenaged girl (15 years 7 months), ...